IMA · ImageneBio, Inc. · Metrics
Market Cap
$57.67M
Shares
11.35M
IMA metrics
57 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$5.08
Market cap
$57.67M
Price action
20 metricsPrice change (1W)
+4.7%
Price change (30D)
-13.0%
Price change (3M)
-9.6%
Price change (6M)
-14.0%
Price change (YTD)
-26.4%
Price change (1Y)
-44.8%
Trailing year
Price change (5Y)
—
52-week high
$9.20
52-week low
$4.55
Change from 52-week high
-44.8%
Change from 52-week low
+11.6%
Annualized volatility
57.7%
Annualized volatility (3M)
47.3%
Beta
1.1
RSI (14D)
40.6
Price vs SMA 50
-9.2%
Price vs SMA 200
-15.3%
Avg volume (3M)
11,876
Relative volume
0.7
Average dollar volume
$66,099
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
11.35M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.4
reciprocal yield 246.4%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-91.0%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-05-15
Profitability
9 metricsGross margin
—
Operating margin
-6,056.4%
Trailing 12 months
Net margin
-5,668.6%
Gross profit (TTM)
—
Operating profit (TTM)
−$58.96M
Net income (TTM)
−$52.48M
Trailing 12 months
Diluted EPS (TTM)
$-2.96
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+571.6%
Year over year · more shares
Revenue CAGR (3Y)
-62.9%
Revenue CAGR (5Y)
-38.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-36.9%
Return on assets
-34.5%
Debt / equity
—
Current ratio
21.5
EBITDA (TTM)
−$58.56M
Free cash flow (TTM)
—
Quick ratio
21.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$94.68M
Total assets
$152.04M
Total debt
$0
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$52.59M
Capital expenditures (TTM)
$414,000
R&D (TTM)
$31.46M
SG&A (TTM)
—
Stock compensation (TTM)
$17.12M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
35
13F filer change QoQ
-4
Institutional ownership
54.9%
Short interest
3 metricsShort interest
0.3%
Latest settlement · 3.4 days to cover
Days to cover
3.4d
Short-squeeze score
33 / 100
Insider activity
2 metricsNet insider buying (90D)
−$17,334
Insider-sentiment score
49 / 100
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1835579
CUSIP
45175G207
13F (30d)
18 filings
18 filers
Visit website
Investor relations